Immunological and Autoimmune Disorders

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Navigating the Healthcare Horizon: Odyssey of Mergers, Funding, and Acquisitions in 2024

Explore More...
Pharma News for Biogen, Astellas, Ascentage

FDA Approves ZURZUVAE for Postpartum Depression; Astellas Drug Acquired in $5.9B Deal Wins FDA Approval; FDA Clearance to Phase III Study of Lisaftoclax; FDA Issues CRL to BLA Resubmission for Remestemcel-L; Bavarian Nordic Updated on its Chikungunya Virus Vaccine; FDA Orphan Drug Designation to ABM-1310

Nutricosmetics Market Outlook

Evaluating the Evolving Trends in the Nutricosmetics Market: The Intersection of Nutrition and Skincare

graft-versus-host-disease-gvhd-treatment

Graft-Versus-Host Disease (GvHD) Treatment Market: A Moving Target For Therapies

Gene Therapies for Dystrophic Epidermolysis Bullosa

Will The Burgeoning Gene Therapies Make a Difference in Dystrophic Epidermolysis Bullosa Patients’ Lives?

Pharma News for Pfizer, Daiichi Sankyo, Kyverna, Servier

Daiichi Sankyo’s Intravenous Iron Replacement Therapy; ANeuroTech’s Adjunctive Anti-depression Drug, ANT-01; Kyverna Therapeutics’s KYV-101 in Lupus Nephritis; Servier Presents Data from Phase 3 INDIGO Trial of Vorasidenib; FDA Approves Pfizer’s ABRYSVO

anca-associated-vasculitis-treatment

ANCA-associated Vasculitis Treatment Market: Unraveling the Complexities

emerging-tlr-7-8-agonists

Role of TLR7/8 Agonists in Treating Various Cancers

emerging-drugs-for-plaque-psoriasis-treatment

What Does the Future of Plaque Psoriasis Treatment Market Look Like?

Drug Delivery Devices Market and Key Companies

How Connected Drug Delivery Devices are Improving the Patient Outcomes?

Pharma News and updates for HUTCHMED, Cytokinetics, Astellas, Seagen, Nanoscope Therapeutics, Cabaletta Bio, Decibel Therapeutics

HUTCHMED’s NDA Submission to FDA for Fruquintinib; Cytokinetics to Discontinue ALS Drug Candidate Following Phase III Trial Failure; Enfortumab Vedotin + Pembrolizumab Approved for Urothelial Carcinoma; Nanoscope Gene Therapy Clears Phase II Retinitis Pigmentosa Trial; FDA Clearance to Cabaletta Bio’s IND Application for CABA-201 for SLE Treatment; European Orphan Drug Designation to Gene Therapy Candidate DB-OTO

Pharma news and updates for Roche, Acadia, Shorla Oncology, Calliditas, Mesoblast, Sanofi, Provention Bio

Sanofi to Acquire Provention Bio; USFDA Committee Votes in Favor Roche’s Polivy; FDA to Review Mesoblast’s GvHD Drug; FDA Approves Acadia’s Daybue ; FDA Approves Nelarabine Injection; Calliditas’s Nefecon Trial Reuslt in IgA Nephropathy

Pharma News and Updates for Incyte, Eisai, Biogen, Reata Pharmaceuticals, Genenta Science, Harbour BioMed, Ikena Oncology

Incyte’s Clinical Trial for Myelofibrosis; Eisai and Bioge’s Leqembi; FDA Approves Reata Pharmaceuticals’ SKYCLARYS; Temferon Lands FDA Orphan Drug Status for Glioblastoma; Harbour BioMed Announces Results from Phase III Trial of Batoclimab; FDA Fast Track Designation to Ikena’s AHR Antagonist IK-175

Biologics in the Nasal Polyposis Treatment Market

Biologics Spark Market Interest In The Nasal Polyposis Treatment Space

Lupus Nephritis Treatment Market Outlook and Emerging Therapies

Lupus Nephritis: A SILENT but SEVERE Systemic Lupus Erythematosus Manifestation

Latest Pharma News and Updates for Ipsen, Chiesi, Takeda, ACELYRIN, Lantern Pharma

Ipsen to Acquire Albireo; Chiesi Farmaceutici to Buy Amryt Pharma; Takeda Presents Phase III Results of TAK-755 for cTTP; ACELYRIN Acquires ValenzaBio; FDA Approves LEQEMBI for Alzheimer’s Disease; Orphan Drug Designation to Lantern Pharma’s LP-284 for MLL

humira-biosimilars-in-psoriatic-arthritis-treatment-market

HUMIRA Biosimilars in the US: The Talk of the Psoriatic Arthritis Treatment Market

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Days
loader